15 results about "Neoplastic cell" patented technology

Tumor glycocalyx may be regarded as a glycan “canopy” above the tumor plasma membrane. Disclosed are methods of treating a neoplastic malignant cell cancer wherein the neoplastic malignant cancer cell has a malignant glycocalyx B. Also disclosed are methods of inducing apoptosis of one or more neoplastic malignant cells and methods of increasing a subject's responsiveness to an immunotherapy wherein the neoplastic malignant cancer cell has a malignant glycocalyx B.

Provided are BCL9 mimetic peptides having a modified a-helical homology domain-2 (HD2) region and, optionally, a cell-penetrating region, compositions comprising the BCL9 mimetic peptides, and methods of inhibiting proliferation of and / or promoting cytotoxicity in a neoplastic cell using the BCL9 mimetic peptides.

The present invention relates to the fields of medicine, cell biology, molecular biology and genetics. In particular, the present invention provides methods to isolate and purify microvesicles from cell culture supernatants and biological fluids. The present invention also provides pharmaceutical compositions of microvesicles to promote or enhance wound healing, stimulate tissue regeneration, remodel scarred tissue, modulate immune reactions, alter neoplastic cell growth and / or mobility, or alter normal cell growth and / or mobility. The present invention also provides compositions of microvesicles to be used as diagnostic reagents, and methods to prepare the compositions of microvesicles.

Macrocyclic chelating agents (I) are provided for the chelation of alpha-emitting radiometal ions, such as actinium-225. Radiometal complexes containing an alpha-emitting radiometal ion linked to the macrocyclic chelating agent via a coordinate linkage are also provided, as are radioimmunoconjugates containing the radiometal complexes covalently linked to a targeting ligand, such as an antibody or an antigen-binding fragment. The radioimmunoconjugates can be produced by click chemistry reactions. Methods for using the radiocomplexes and radioimmunoconjugates for the selective targeting of neoplastic cells in radiotherapy and for the treatment of neoplastic diseases and disorders are also described.

The present disclosure provides a pharmaceutical association comprising at least one growth factor receptor-binding compound, which activates at least one growth factor receptor of a neoplastic cell, and at least one adhesion protein inhibitor which inhibits at least one transmembrane cell adhesion protein of said neoplastic cell.

The utility model discloses a colorectal cancer micro tumor cell culture device which comprises a culture dish and a sealing cover, the sealing cover covers and presses the top of the culture dish, the outer walls of the culture dish and the sealing cover are sleeved with two semi-arc-shaped cladding plates, the interiors of the two semi-arc-shaped cladding plates are of a cavity structure, and the two semi-arc-shaped cladding plates are arranged in the cavity structure. And the internal cavities of the two semi-arc cladding plates are filled with purified water. According to the utility model, purified water filled in the semi-arc-shaped cladding plate is used as a high-specific-heat-capacity heating medium, and a closed-loop temperature control system constructed by the electric heating wire and the top thermometer is combined, so that the temperature of the inner cavity of the culture dish can be continuously maintained after the culture dish is separated from an incubator environment, and the interference of external environment temperature fluctuation is effectively resisted; the method is especially suitable for cross-laboratory cooperation or in-situ detection scenes requiring frequent sample transfer; through the collaborative design of the arc-shaped through groove and temperature control, the proper temperature can be ensured while the colorectal cancer cells are observed, and temperature loss is avoided.

The present disclosure provides compositions for inhibiting interaction of Siglec-5 with its cognate ligand on cancer cells and their use as checkpoint inhibitors in the treatment of neoplastic disorders. A method for the treatment and / or prevention of a cancer that expresses a Siglec-5 ligand in a subject is provided comprising administering to the subject a molecule that inhibits the interaction between Siglec-5 and a Siglec-5 ligand expressed on the cancer cell. In some aspects, the subject is identified as having a cancer expressing a Siglec-5 ligand. Preferably, the molecule is a monoclonal antibody against Siglec-5.

The present invention comprises synthetic peptides derived from the venom of the H. junceus scorpion with anti-metastatic properties, as well as compositions of synthetic peptides derived from the venom of the H. junceus scorpion and its variants, which are obtained from recombinant or synthesis techniques, with anti-metastatic properties and which are effective against tumour cells or small cell lung cancer cells.

Compositions and methods for treating cancer are provided. In particular, the compositions comprise an encapsulated CD1d-restricted invariant Natural Killer T (iNKT) cell antigen, such as glycosphingolipid, for example, α-galactosylceramide. Methods of administering the compositions in combination with a therapy that induces the death of neoplastic cells in the subject are provided.

The invention discloses an integrated microfluidic biosensor chip based on a micro-column array D-type optical fiber, and belongs to the field of biological detection. The integrated microfluidic biosensing chip based on the micro-column array D-type optical fiber comprises a fiber-based micro-column array D-type sensing optical fiber, the side edge polishing surface of the fiber-based micro-column array D-type sensing optical fiber is provided with a periodic micro-column array; the surface of the microcolumn array is sequentially coated with a sensibilization layer and a specific modification layer; the raw material of the sensitization layer comprises a sensitization material, the sensitization material comprises an MXene material and / or a metal nano material, and the raw material of the specific modification layer comprises a biological aptamer material. The micro-column array structure can be used as a cell capture enhancement interface to form a large number of capture sites, so that the contact area between cells and the surface of the chip is increased, and the cell capture efficiency is improved. The intensity of an evanescent field of the optical fiber can be greatly enhanced by the sensibilization layer, specific recognition is realized by the biological aptamer material, and good sensitivity and detection precision can also be realized for extremely-low-concentration circulating tumor cells.

Aspects of the disclosure include methods for treating a myeloproliferative neoplasm. Methods according to certain embodiments include co-administering to a subject a Janus kinase (JAK) inhibitor and a telomerase inhibitor comprising an oligonucleotide and a lipid moiety linked to the 5′ and / or 3′ end of the oligonucleotide. Methods for inducing apoptosis of a myeloproliferative neoplasm cell by contacting the cell with an amount of a JAK inhibitor and a telomerase inhibitor sufficient to induce apoptosis are also described. Compositions having a JAK inhibitor and a telomerase inhibitor for practicing the subject methods are also provided.

Soluble multispecific protein that binds a target peptide MHC complex on a target cell and a surface receptor on an immune cell, incorporating a half life extending region (eg., Fc region) attached via a cleavable linker. Inclusion in the linker of a substrate sequence for a protease specific to the tumour microenvironment selectively releases an active portion of the protein from the half life extending region at the tumour site. Release of the active complex increases its potency for mediating T cell signalling at an immune synapse with tumour cells presenting the target pMHC.

The invention belongs to the technical field of biological medicines, and discloses application of an SEC14L4 inhibitor in preparation of a medicine for treating esophageal squamous carcinoma. SEC14L4 is determined as a key cancer promoting gene of esophageal squamous carcinoma for the first time, is abnormally highly expressed in esophageal squamous carcinoma tissues and is related to poor prognosis details of a patient, so that the research blank in the field is filled up, and a new theoretical basis is provided for in-depth research of esophageal squamous carcinoma pathogenesis; the oligonucleotide molecule and the retrovirus inhibitor designed by taking the SEC14L4 gene as the target spot can specifically recognize and silence the abnormally high-expressed SEC14L4 gene in the esophageal squamous carcinoma tissue, accurately act on tumor cells, inhibit the malignant phenotype of the tumor cells and improve the treatment safety. On the basis of a targeted treatment strategy of the gene, the limitation of a traditional treatment means is broken through, a brand-new treatment choice is provided for esophageal squamous cell carcinoma patients, particularly advanced patients and chemotherapy drug resistance patients, and the gene has great clinical transformation value and social significance.